Markets:

Overview

News

Currencies

International

Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

99.33 +3.06 (+3.18%)

Streaming Delayed Price Updated: 11:51 AM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

January 28, 2025

From GeneDx

Via Business Wire

GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

January 27, 2025

Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name.

Via MarketBeat

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 17, 2025

From GeneDx

Via Business Wire

Stocks Moving Lower Despite Encouraging Inflation Data ↗

January 14, 2025

Via Talk Markets

Topics Economy Stocks / Equities

Why NASDAQ:WGS qualifies as a high growth stock. ↗

December 11, 2024

Why the high growth investor may take a look at GENEDX HOLDINGS CORP (NASDAQ:WGS).

Via Chartmill

GeneDx Announces Preliminary 2024 Financial Results

January 13, 2025

From GeneDx

Via Business Wire

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

January 09, 2025

From GeneDx

Via Business Wire

I’m Not Worried About This Pullback ↗

January 08, 2025

Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree.

Via Talk Markets

Topics Cryptocurrencies Stocks / Equities

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

January 08, 2025

From GeneDx

Via Business Wire

IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development ↗

January 06, 2025

GeneDx provides whole and exome gene sequencing to identify rare diseases.

Via Investor's Business Daily

Topics Artificial Intelligence

Focus On High Cash Flow Companies. You Are The Company You Keep. ↗

January 05, 2025

There are too many stocks acting well to expect a bear market right now.

Via Talk Markets

Topics Stocks / Equities

Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly ↗

January 04, 2025

Energy plays, a biotech and a brokerage also are flashing buy signals or setting up.

Via Investor's Business Daily

Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday ↗

January 03, 2025

US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters.

Via Benzinga

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

January 02, 2025

From GeneDx

Via Business Wire

Best Performing Stocks Of 2024 ↗

January 02, 2025

A look at the some of best performing stocks in 2024 of current Russell 3,000 members.

Via Talk Markets

Topics Stocks / Equities

The Top 5 Mid Cap Stocks Of 2024 ↗

December 19, 2024

These high-fliers are on the leading edge of innovation.

Via Talk Markets

Topics Stocks / Equities

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

From GeneDx

Via Business Wire

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

December 05, 2024

From GeneDx

Via Business Wire

GeneDx to Participate in Upcoming Investor Conference

November 22, 2024

From GeneDx

Via Business Wire

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

November 19, 2024

From GeneDx

Via Business Wire

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

November 18, 2024

From GeneDx

Via Business Wire

Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year ↗

November 16, 2024

Via The Motley Fool

Don’t Confuse Brains With A Bull Market, Or Price With Value ↗

November 10, 2024

If you are interested in the stock market, maybe it is time to stop focusing on The Fed.

Via Talk Markets

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

November 07, 2024

From GeneDx

Via Business Wire

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

November 04, 2024

From GeneDx

Via Business Wire

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗

November 03, 2024

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Via Benzinga

Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results ↗

October 29, 2024

Via Benzinga

Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views ↗

October 29, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 29, 2024

Via Benzinga

Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance ↗

October 29, 2024

GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.